Transcarent, a fast-growing health tech company founded in 2020 by health tech investor Glen Tullman, has announced $126 million in Series D funding. The investment round was led by venture capital giants General Catalyst and 7wireVentures, with Tullman serving as a managing partner at the latter. The funds will be used to enhance the company’s artificial intelligence capabilities, expand its business and explore potential acquisitions, according to Tullman. To date, Transcarent has raised approximately $450 million in funding.
As an emerging company that leverages technology to improve care and reduce costs for organizations offering health benefits to their employees, Transcarent distinguishes itself from other healthcare navigation and virtual care companies with similar goals. With this new funding round, the company aims to continue pushing the boundaries of what technology can achieve in healthcare.
This article is exclusive to STAT+ subscribers. Subscribe now to gain access to additional insights on the technologies transforming healthcare and enjoy unlimited access to award-winning journalism and exclusive events.